Novel Mononuclear Ruthenium(II) Compounds in Cancer Therapy |
Anchuri, Shyam Sunder
(Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy)
Thota, Sreekanth (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) Yerra, Rajeshwar (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) Devarakonda, Krishna Prasad (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) Dhulipala, Satyavati (Department of Pharmacology, Teegala Krishna Reddy College of Pharmacy) |
1 | Ang WH, Dyson PJ (2006). Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Euro J Inorg Chem, 20, 4003-18. |
2 | Beraldo H, Gambino D (2004). The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Rev Med Chem, 4, 31-9. DOI |
3 | Bergamo A, Sava G (2007). Ruthenium complexes can target determinants of tumor malignancy. Dalton Trans, 13, 1267-72. |
4 | Bruijnincx PCA, Sadler PJ (2009). Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Adv Inorg Chem, 61, 1-62. DOI |
5 | Brunton LL, Lazo JS, Parker KL (2005). Pharmacological Basis of Therapeutics. MCGRAW- HILL, New York. |
6 | Clairs SA, Paul JD (2001). Ruthenium in medicine: current clinical uses and future prospects. Platinum Met Rev, 45, 62-9. |
7 | Clarke MJ, Zhu F, Frasca DR (1999). Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev, 99, 2511-34. DOI |
8 | Clarkson BD, Burchenal JH (1965). Priliminary screening of antineoplastic drugs. Prog Clin Cancer, 1, 625-9. |
9 | Cristiano MP, Cardoso DC, Da Silva Paula MM, Costa-Campos L (2008). Antinociceptive effect of a ruthenium complex in mice. Auton & Autac Pharmacol, 28, 103-8. DOI |
10 | Dyson PJ (2007). Systematic design of a targeted organometallic antitumour drug in pre-clinical development. CHIMIA Int J Chem, 61, 698-703. DOI |
11 | Folkman J, Kalluri R (2004). Cancer without disease. Nature, 427, 787. DOI |
12 | Hadda TB, Mehmetakkurt, Baba MF, et al (2009). Anti-tubercular Activity of Ruthenium(II) Complexes with Polypyridines. J Enzy Inhib Med Chem, 24, 457-63. DOI |
13 | Gianferrara T, Bratsos I, Alessio E (2009). A categorization of metal anticancer compounds based on their mode of action. Dalton Trans, 37, 7588-98. |
14 | Gothoskar SV, Ranadive KJ (1971) Anticancer screening of SAN-AB: An extract of marking nut Semicarpus anacardium. Indian J Exp Biol, 9, 372-5. |
15 | Govender P, Renfrew AK, Clavel CM, et al (2011). Antiproliferative activity of chelating N, O- and N, N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Trans, 40, 1158-67. DOI |
16 | Mazumder UK, Gupta M, Maiti S, Mukherjee M (1997). Antitumor activity of Hygrophila spinosa on Ehrlich ascites carcinoma and sarcoma-180 induced mice. Indian J Exp Biol, 35, 473-7. |
17 | Hartinger CG, Dyson PJ (2009). Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem Soc Rev, 38, 391-401. DOI |
18 | Hartinger CG, Jakupec MA, Zorbas-Seifried S, et al (2008). KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients. Chem and Biodiver, 5, 2140-55. DOI |
19 | Hogland HC (1982). Hematological complications of cancer chemotherapy. Semin Oncol, 9, 95-102. |
20 | Meyer BN, Ferringin NR, Putman JE, et al (1982). Brine shrimp. A convenient general bioassay for active constituents. Planta Medica, 45, 31-4. DOI ScienceOn |
21 | Newcomb JR, Rivnay B, Bastos CM, et al (2003). In vitro immunomodulatory activity of ruthenium complexes. Inflamm Res, 52, 263-71. |
22 | Noaman E, Zahran AM, Kamal AM, Omran MF (2002). Vitamin E and selenium administration as a modulator of antioxidant defense system: biochemical assessment and modification. Biol Trace Elem Res, 86, 55-64. DOI |
23 | Novakova O, Brabec V (2006). DNA binding mode of Ruthenium complexes and relationship to tumour cell toxicity. Drug Res Updates, 9, 111-22. DOI |
24 | Paula MM, Pich CT, Petronilho F, et al (2005). Antioxidant activity of new ruthenium compounds. Redox Rep, 10, 1-6. |
25 | Sendiero DA, Shoemaker RH, Paul KD (1998). Evaluation of soluble tetrazolium/formazan assay for cell growth % drug sensitivity in cultures using human and other cells lines. Cancer Res, 48, 4827-33. |
26 | Prasad SB, Giri A (1994). Antitumor effect of cisplatin against murine ascites Dalton's lymphoma. Ind J Exp Biol, 32, 155-62. |
27 | Sava G, Clerici K, Capozzi I et al (1999b). Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumours. Anti-Cancer Drugs, 10, 129-38. DOI |
28 | Scott MP (2003). A twist in the Hedgehog's tale. Nature, 425, 780-2. DOI ScienceOn |
29 | Shyam Sunder A, Sreekanth T, Rajeshwar Y, Satyavati D (2012). In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium(II) Compounds. Lett Drug Design Disc, 9, 421-5. DOI |
30 | Sreekanth T, Karki SS, Jayaveera KN et al (2010). Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes. J Enzyme Inhib Med Chem, 25, 513-9. DOI |
31 | Süss-Fink G (2010). Arene ruthenium complexes as anticancer agents. Dalton Trans, 39, 1673-88. DOI |
32 | Verweij J, Dejonge MJA (2000). Achievements and future of chemotherapy. Eur J Cancer, 36, 1479-87. DOI ScienceOn |